GVR Report cover U.S. End Stage Renal Disease Market Size, Share & Trends Report

U.S. End Stage Renal Disease Market Size, Share & Trends Analysis Report By Treatment (Transplant, Dialysis, Peritoneal Dialysis, Hemodialysis, Wearable Artificial Kidney), And Segment Forecasts, 2024 - 2030

  • Report ID: GVR-4-68040-239-7
  • Number of Pages: 90
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2023
  • Industry: Healthcare

Market Size & Trends

The U.S. end stage renal disease market size was valued at USD 15.95 billion in 2023 and is anticipated to grow at a CAGR of 13.1% over the forecast period of 2024 to 2030. The market is witnessing growth owing to factors such as rising incidence of kidney failures and chronic kidney diseases (CKD), and enormous demand for dialysis procedures. Increasing healthcare spending, government initiatives, and high disposable income are a few other factors contributing toward market growth.

U.S. End Stage Renal Disease Market size and growth rate, 2024 - 2030

U.S. end stage renal disease market accounted for 14.0% of the global end stage renal disease market in 2023. Increase in the number of initiatives associated with treatment of chronic kidney disease is expected to boost market growth. For instance, in 2019, U.S. Department of Health & Human Services launched President Trump’s Advancing Kidney health initiative. In addition, favorable reimbursement policies for patients suffering from end stage renal disease in this region may positively impact the market.

As per the National Kidney Foundation, CKD has affected around 37 million people in the U.S. Approximately 80 million people, which is around 1 in 3 American adults, are at risk of chronic kidney disease, and it is the ninth leading cause of death in this region. CKD is more common in women as compared to that in men. The number of patients continues to increase at a rate of 5% to 7% per year, and patients require kidney transplant or dialysis to survive. Increasing prevalence of CKD and healthcare spending by the Medicare, which is a U.S, federal agency, are expected to drive the market growth.

Market Concentration & Characteristics

Rising number of initiatives and increasing awareness among kidney failure patients about choosing peritoneal dialysis or hemodialysis are expected to boost the demand for end stage renal disease (ESRD) treatment, thereby fueling the industry growth during the forecast period.

U.S. End Stage Renal Disease Market Concentration & Characteristics

Launching technologically advanced products may lead to higher effectiveness, which is expected to support the increase in product demand. Recently, key companies are launching products with almost similar features to compete with each other. For instance, in January 2020, Fresenius Medical introduced its latest 4008A dialysis machine with the aim to improve dialysis treatment for patients who are surviving from end stage renal disease. Such advanced product launches are reducing the sale of some of the existing products.

Increased merger & acquisition (M&A) activities, collaboration and partnerships between companies to provide advanced services and solutions are expected to boost the industry growth over the forecast period. For instance, in February 2019, Fresenius Medical Care announced the acquisition of NxStage Medical, Inc. to strengthen its position in home-based hemodialysis machines market.

The U.S. FDA expanded and finalized 510(k) registration route for safety and performance of medical devices. The enhanced industry approval pathway is focused on analyzing and assessing performance issues & device safety by demonstrating substantial equivalence. However, increasing government initiatives, supportive regulations and laws, and increasing awareness in the community are expected to drive the market growth.

Treatment Insights

The dialysis segment accounted for the largest share of 78.13% in 2023. According to the U.S. National Kidney Foundation, end-stage kidney failure occurs due to only 10% to 15% of kidneys functioning normally. Dialysis filters purify fluids and blood using machines such as dialyzers and water treatment systems. There are majorly two types of dialysis including peritoneal dialysis and hemodialysis. The increasing prevalence of Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD) is further boosting the demand for dialysis.

U.S. End Stage Renal Disease Market share and size, 2023

The transplant segment is expected to register a considerable CAGR over the forecast period as it can help recover end-stage renal disease. Factors such as obesity, lifestyle changes, and diabetes lead to severe kidney failures that require transplant. According to the United Network for Organ Sharing (UNOS), over 25,000 kidney transplants were performed in the 2022. Owing to lesser availability of kidneys in comparison to the list of people waiting, the segment is expected to witness higher demands in the forthcoming years.  

Key U.S. End Stage Renal Disease Company Insights

Companies operating in the market are Nipro Corporation, Fresenius Medical Care AG & Co. KGaA, Medtronic, B. Braun Melsungen AG, BD, Baxter, Asahi Kasei Medical co., Ltd, Cantel Medical, Nikkiso Co. Ltd, JMS Co. Ltd. Key companies are adopting various strategies such as new product launch, mergers and acquisitions to gain more market share.

Key companies are strategizing to geographically expand their businesses and build more warehouses at various places so that they can run their business through various local channels in the country with a high patient count. Moreover, key companies are constantly incorporating technologies that can meet specific requirements of patients.

Key U.S. End Stage Renal Disease Companies:

  • Nipro Corp.
  • Fresenius Medical Care AG & Co. KGaA
  • Baxter International, Inc.
  • Medtronic Plc
  • B. Braun Melsungen AG
  • BD
  • Asahi Kasei Medical Co., Ltd.
  • Cantel Medical
  • Nikkiso Co., Ltd.
  • JMS Co. Ltd.

Recent Developments

  • In October 2023, Ardelyx announced the FDA approval of Tenapanor for reducing serum phosphorus in adults with chronic kidney disease on dialysis

  • In September 2023, the US FDA approved Jardiance(empagliflozin) 10 mg tablets for reducing the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease (CKD) at risk of progression

U.S. End Stage Renal Disease Market Report Scope

Reports Attribute


Market size value in 2024

USD 17.94 billion

Revenue forecast in 2030

USD 37.79 billion

Growth rate

CAGR of 13.1% from 2024 to 2030

Actual data

2018 - 2023

Forecast period

2024 - 2030

Quantitative units

Revenue in USD million/billion and CAGR from 2024 to 2030

Report coverage

Revenue forecast, company share, competitive landscape, growth factors & trends

Segments covered


Country scope


Key companies profiled

Nipro Corp.; Fresenius Medical Care AG & Co. KGaA; Medtronic; B. Braun Melsungen AG; BD; Baxter; Asahi Kasei Medical Co., Ltd.; Cantel Medical; Nikkiso Co. Ltd.; JMS Co. Ltd.

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional, and segment scope


U.S. End Stage Renal Disease Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. end stage renal disease market report based on treatment:

  • Treatment Outlook (Revenue, USD Million, 2018 - 2030)

    • Transplant

    • Dialysis

      • Peritoneal Dialysis

      • Hemodialysis

      • Wearable Artificial Kidney

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.